
Do You Know Your Brain Care Score?
Noor F. Shaik, MD, PhD
Could a new risk score focused on the brain help change that? The McCance Brain Care Score (BCS) aims to empower patients and practitioners to better care for their brains.
We already have the American Heart Association's (AHA) PREVENT online calculator for predicting the 10- and 30-year risk for heart attack, stroke, and heart failure, as well as the Framingham Risk Calculator that estimates 10-year risk for atherosclerotic cardiovascular disease, including strokes and heart attacks. While they incorporate variations of the known modifiable risk factors, the BCS takes a more holistic, patient-forward approach and addresses dementia and late-life depression. Here are some aspects that make it stand out to me.
1. Intuitive scoring system. The BCS incorporates well-known modifiable risk factors (eg, hypertension, hyperlipidemia, smoking, alcohol use) into a 21-point score rather than a risk percentage. Each risk factor gets a number. For hypertension, the biggest modifiable contributor to stroke risk, this ranges from 0 to 3, with more points for better blood pressure control.
The McCance Brain Care Score
2. Gamification of health. Adding the points across several modifiable risk factors yields a score of up to 21, with higher scores linked to better neurologic outcomes. A 5-point higher BCS was associated with an approximate 50% lower risk for stroke in those under 60 years of age.
This scoring system capitalizes on the gamification of health, a concept that is increasingly popular because of health apps and wearables such as the Apple Watch and FitBit. Nearly 1 in 3 US adults use health wearables that may nudge them toward health-promoting behaviors such as hitting benchmarks for daily steps or weekly physical activity. Gamification tactics have been shown to improve medication adherence; whether they can lead to sustained behavioral changes remains to be seen. I like the idea of improving people's health while making it a fun challenge to get a 'high' score.
3. Practicality. The BCS presents the modifiable risk factors as opportunities for change and capitalizes on this by giving people goals. For example, the score provides multiple ways to get points for a healthier diet, such as eating 4.5 servings of fruit and vegetables per day or less than 36 oz of sweetened beverages (such as juice and soda) per week. The targets are specific, measurable, and realistic.
4. Widespread applicability and generalizability. Another highlight of the BCS is that it can be used by anyone, even those who have already had a stroke. The score also incorporates risk factors tied to dementia and late-life depression. Given that dementia cases are expected to double by 2060, this has broad application. The BCS shares risk factors with cardiovascular disease and multiple cancers, allowing people to use it to reduce their chances of multiple diseases. For example, in UK adults aged 40-69 years, a 5-point higher BCS was associated with a 43% lower risk of developing cardiovascular disease and a 31% lower risk for leading cancers (specifically, a 66% lower risk for lung cancer, 21% lower risk for colorectal cancer, and 16% lower risk for breast cancer).
5. Increasing popularity. The score is very new. The first validation study was published less than 2 years ago. But since then, there have been at least five other papers on the score's utility, and the questionnaire has even been adapted by The New York Times .
Have you or any of your patients taken the BCS? It might be a fun poster to have in your doctor's office or waiting room, and it could serve as a focal point to discuss positive habits and opportunities for change. With these strategies, we can empower our patients to proactively reduce their risk for stroke, heart disease, and cancer, and help them live longer, healthier lives.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
Vistagen to Present at the BTIG Virtual Biotechnology Conference
SOUTH SAN FRANCISCO, Calif., July 24, 2025--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that President and Chief Executive Officer, Shawn Singh, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, July 29, at 10 a.m. Eastern Time. The Fireside Chat will be livestreamed for registered investors, and a recording will be available on the BTIG conference portal for conference attendees following the event. If you would like to schedule a one-on-one meeting with Vistagen's management team, please contact your BTIG representative. To join the conference, email uscorporateaccess@ About Vistagen Headquartered in South San Francisco, CA, Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines. Pherines specifically and selectively bind as agonists on peripheral receptors on human nasal chemosensory neurons and are designed to rapidly activate olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. They are designed to achieve therapeutic benefits without requiring absorption into the blood or uptake into the brain, giving them the potential to be a safer alternative to other pharmacological options if successfully developed and approved. Vistagen is passionate about developing transformative treatment options to improve the lives of individuals underserved by the current standard of care for multiple highly prevalent indications, including social anxiety disorder, major depressive disorder, and multiple women's health conditions, such as vasomotor symptoms (hot flashes) associated with menopause. Connect at View source version on Contacts Investor Inquiries: Mark A. McPartlandmarkmcp@ Media Inquiries: Michelle P. Wellingtonmwellington@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 minutes ago
- Yahoo
What to Expect From Insulet's Q2 2025 Earnings Report
Insulet Corporation (PODD), headquartered in Acton, Massachusetts, operates as an innovative medical device company. Valued at $20.2 billion by market cap, the company develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The insulin infusion systems maker is expected to announce its fiscal second-quarter earnings for 2025 before the market opens on Thursday, Aug. 7. Ahead of the event, analysts expect PODD to report a profit of $0.93 per share on a diluted basis, up 69.1% from $0.55 per share in the year-ago quarter. The company beat the consensus estimates in three of the last four quarters while missing the forecast on another occasion. More News from Barchart NVDA Broken Wing Butterfly Trade Targets A Profit Zone Between 150 and 160 Is Opendoor Stock a Buy at New 52-Week Highs? Billionaire Peter Thiel is Betting Big on Stablecoins. Should You Buy the "MicroStrategy of Ethereum," Too? Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. For the full year, analysts expect PODD to report EPS of $4.33, up 33.6% from $3.24 in fiscal 2024. Its EPS is expected to rise 25.4% year over year to $5.43 in fiscal 2026. PODD stock has outperformed the S&P 500 Index's ($SPX) 14.5% gains over the past 52 weeks, with shares up 45.7% during this period. Similarly, it outperformed the Health Care Select Sector SPDR Fund's (XLV) 8.3% dip over the same time frame. Insulet's strong performance is driven by robust U.S. growth, expanding international demand, and the success of its Omnipod insulin delivery systems. With continued innovation and global expansion, the company is well-positioned for long-term growth in the diabetes care market, making it a promising investment in the medical technology sector. On May 8, PODD reported its Q1 results, and its shares closed up more than 20% in the following trading session. Its adjusted EPS of $1.02 surpassed Wall Street's expectations of $0.81. The company's revenue was $569 million, topping Wall Street forecasts of $542.1 million. Analysts' consensus opinion on PODD stock is bullish, with an overall 'Strong Buy' rating. Out of 23 analysts covering the stock, 19 advise a 'Strong Buy' rating, two suggest a 'Moderate Buy,' and two give a 'Hold.' PODD's average analyst price target is $343.77, indicating a potential upside of 19.9% from the current levels. On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Sign in to access your portfolio
Yahoo
2 minutes ago
- Yahoo
Agilent Technologies' Q3 2025 Earnings: What to Expect
Santa Clara, California-based Agilent Technologies, Inc. (A) is a global leader in providing application-focused solutions to the life sciences, diagnostics, and applied chemical markets. Valued at a market cap of $33.9 billion, the company designs and manufactures a broad portfolio of analytical instruments, software, consumables, and services. It is scheduled to announce its fiscal Q3 earnings for 2025 after the market closes on Wednesday, Aug. 27. Before this event, analysts project this healthcare company to report a profit of $1.37 per share, up 3.8% from $1.32 per share in the year-ago quarter. The company has surpassed Wall Street's bottom-line estimates in each of the last four quarters. Its earnings of $1.31 per share in the previous quarter outpaced the consensus estimates by 4%. More News from Barchart NVDA Broken Wing Butterfly Trade Targets A Profit Zone Between 150 and 160 Is Opendoor Stock a Buy at New 52-Week Highs? Billionaire Peter Thiel is Betting Big on Stablecoins. Should You Buy the "MicroStrategy of Ethereum," Too? Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. For the full year, analysts expect A to report EPS of $5.59, up 5.7% from $5.29 per share in fiscal 2024. Furthermore, its EPS is expected to grow 8.8% year-over-year to $6.08 in fiscal 2026. A has fallen 8.6% over the past 52 weeks, underperforming both the S&P 500 Index's ($SPX) 14.5% return and the Health Care Select Sector SPDR Fund's (XLV) 8.3% loss over the same time frame. Agilent Technologies reported impressive Q2 performance on May 28, and its shares surged 2.2% in the following trading session. Due to growth in its life sciences and diagnostics markets revenue and a rise in CrossLab segment's sales, the company's overall revenue improved 6% year-over-year to $1.7 billion, topping consensus estimates by 2.5%. Moreover, its adjusted EPS of $1.31 advanced 7.4% from the prior-year quarter, exceeding Wall Street expectations by 4%. A's effective Ignite Transformation initiative supported its Q2 results. Looking ahead to fiscal 2025, A expects revenue to range between $6.7 and $6.8 billion, and projects adjusted EPS in the range of $5.54 to $5.61. Wall Street analysts are moderately optimistic about A's stock, with an overall "Moderate Buy" rating. Among 16 analysts covering the stock, eight recommend "Strong Buy," and eight advise 'Hold.' The mean price target for A is $138.57, indicating a 16% premium from the current levels. On the date of publication, Neharika Jain did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on